CD8A and breast cancer: We documented a numerically higher NPV for ISCR; however, larger studies are required to evaluate the ISCR, CD3, and CD8 cell densities and the association with endpoints such as pCR, time to progression, and overall survival in early BC patients, as well as PPV and NPV of these biomarkers.